Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer (Neo-shorter)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02001506 |
Recruitment Status :
Completed
First Posted : December 5, 2013
Last Update Posted : August 29, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Drug: FEC3-D3 | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 250 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Phase III Trial of Neoadjuvant Chemotherapy With 3 Cycles of FEC Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Adriamycin Plus Cyclophosphamide Followed by 4 Cycles of Docetaxel in Node-positive Breast Cancer |
Study Start Date : | November 2012 |
Actual Primary Completion Date : | December 2015 |
Actual Study Completion Date : | December 2015 |
Arm | Intervention/treatment |
---|---|
Active Comparator: FEC3-D3
3 cycles of FEC followed by 3 cycles of Docetaxel Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks Docetaxel 75 mg/m2, every 3 weeks |
Drug: FEC3-D3
Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks Docetaxel 75 mg/m2, every 3 weeks Other Names:
|
No Intervention: AC4-D4
4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks Docetaxel 75 mg/m2, every 3 weeks |
- pathologic complete response (pCR) between two arms [ Time Frame: within the first 30 days (plus or minus 3 days) after surgery ]
- 3 year-disease free survival between two arms [ Time Frame: 3 year after surgery ]
- Correlation of pCR and Ki-67 expression at baseline and D14 tumor specimen
- 3 year-disease free survival
- Correlation of pCR and biomarkers such as Ki-67 expression
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Performance status 0 or 1
- Clinically stage 2 or 3 with histologically proven lymph node involvement
- Tumor or lymph node greater than 1.5 cm
Exclusion Criteria:
- Pregnancy or lactation
- Prior chemotherapy or radiotherapy for any malignancy
- Documented history of cardiac disease contraindicating anthracyclines
- Currently active infection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02001506
Korea, Republic of | |
Asan Medical Center | |
Seoul, Korea, Republic of, 05505 |
Principal Investigator: | Sung-Bae Kim, MD, PhD | Asan Medical Center |
Responsible Party: | Sung-Bae Kim, Professor, Asan Medical Center |
ClinicalTrials.gov Identifier: | NCT02001506 |
Other Study ID Numbers: |
2012-0116 |
First Posted: | December 5, 2013 Key Record Dates |
Last Update Posted: | August 29, 2017 |
Last Verified: | August 2017 |
breast cancer neoadjuvant different number of chemotherapy cycles |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Docetaxel Epirubicin Antineoplastic Agents |
Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors |